| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5733886 | BAUSCH | Compositions of clindamycin and benzoyl peroxide for acne treatment |
Mar, 2015
(9 years ago) | |
| US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US9504704 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US10137142 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(5 years from now) | |
| US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(5 years from now) | |
Onexton is owned by Bausch.
Onexton contains Benzoyl Peroxide; Clindamycin Phosphate.
Onexton has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Onexton are:
- US5733886
Onexton was authorised for market use on 23 October, 2008.
Onexton is available in gel;topical dosage forms.
Onexton can be used as topical treatment of acne vulgaris in patients 12 years or older, treatment of acne.
The generics of Onexton are possible to be released after 05 August, 2029.
Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 23 October, 2008
Treatment: Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne
Dosage: GEL;TOPICAL
ONEXTON family patents
